Octavio Espinoza - Feb 27, 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Financial Officer
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
Stock symbol
LGND
Transactions as of
Feb 27, 2024
Transactions value $
$59,180
Form type
4
Date filed
2/29/2024, 06:50 PM
Previous filing
Feb 16, 2024
Next filing
May 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +7.21K +33.65% $0.00 28.6K Feb 27, 2024 Direct F1
transaction LGND Common Stock Options Exercise $44.5K +799 +2.79% $55.75 29.4K Feb 28, 2024 Direct
transaction LGND Common Stock Options Exercise $8.01K +140 +0.48% $57.22 29.6K Feb 28, 2024 Direct
transaction LGND Common Stock Options Exercise $19K +325 +1.1% $58.49 29.9K Feb 28, 2024 Direct
transaction LGND Common Stock Sale -$12.4K -140 -0.47% $88.46 29.8K Feb 28, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -799 -21.78% $0.00 2.87K Feb 28, 2024 Common Stock 799 $55.75 Direct F2
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -140 -1.78% $0.00 7.72K Feb 28, 2024 Common Stock 140 $57.22 Direct F3
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -325 -16.82% $0.00 1.61K Feb 28, 2024 Common Stock 325 $58.49 Direct F4
transaction LGND Employee Stock Option (right to buy) Award $0 +29.3K $0.00 29.3K Feb 27, 2024 Common Stock 29.3K $89.20 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F2 As per the separation of OmniAb Inc. from the issuer, 2,039 stock options were vested and exercisable as of November 1, 2022, whereas 1,629 options vest in 16 substantially equal monthly installments beginning on November 13, 2022.
F3 As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022.
F4 The stock option is fully vested and exercisable.
F5 The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.